On May 01, 2014, CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, reported financial results for the 3 months ended March 31, 2014, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR), shares after opening at $3.10 moved to $3.62 on last trade day and at the end of the day closed at $3.55. Company price to sales ratio in past twelve months was calculated as 657.46 and price to cash ratio as 5.11. CytRx Corporation (NASDAQ:CYTR), showed a positive weekly performance of 11.64%.
On May 01, 2014, Vical Incorporated (NASDAQ:VICL), reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter of 2014 was $3.5 million, or $0.04 per share, compared with a net loss of $9.3 million, or $0.11 per share, for the first quarter of 2013. Vical Incorporated (NASDAQ:VICL), shares advanced 7.08% in last trading session and ended the day on $1.21. Vical Incorporated (NASDAQ:VICL), return on equity ratio is recorded as -45.20% and its return on assets is -41.30%. Vical Incorporated (NASDAQ:VICL), yearly performance is -65.03%.
The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announced the presentation of new pre-clinical data from ALN-PCSsc, targeting PCSK9 for the treatment of hypercholesterolemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), shares moved up 9.89% in last trading session and was closed at $54.43, while trading in range of $ 48.74 – 54.48. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), year to date (YTD) performance is -15.35%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), gained 10.58% after the company announced that HETLIOZ(TM) is now available. This is the 1st treatment that has been approved by the Food & Drug Administration for Non-24-Hour-Sleep-Wake Disorder. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), weekly performance is 6.30%. On last trading day company shares ended up $14.69. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), distance from 50-day simple moving average (SMA50) is -4.55%. Analysts mean target Price for the company is $24.33.
Leave a Reply